Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at
Wall Street
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs